Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7673396 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Stage I | EXPERIMENTAL | Participants with advanced solid tumors harboring RAS mutations will receive multiple ascending doses of RO7673396, as per a pre-defined dosing regimen until unacceptable toxicity or disease progression (PD) and/or loss of clinical benefit as determined by the investigator. |
| Stage II | EXPERIMENTAL | Participants with advanced solid tumors harboring RAS mutations will receive RO7673396 at the dose determined in Stage 1, until unacceptable toxicity or PD and/or loss of clinical benefit as determined by the investigator. |
| Name | Type | Description |
|---|---|---|
| RO7673396 | DRUG | RO7673396 will be administered as per the schedule specified in the protocol. |
Inclusion Criteria: * Histologically documented, locally advanced, recurrent, or metastatic incurable solid tumors * Participants with measurable disease according to RECIST v1.1 assessed by the investigator * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
RO7673396 is an investigational small molecule being developed for the treatment of advanced solid tumors that harbor rat sarcoma viral oncogene homolog (RAS) mutations. It is currently in Phase 1 clinical development for neoplasms, which are abnormal growths of tissue that can be benign or malignant.
RO7673396 targets tumors that harbor rat sarcoma viral oncogene homolog (RAS) mutations. The drug is designed to address cancers with these specific genetic alterations, which are common drivers of tumor growth. It is being studied in patients with advanced solid tumors that test positive for RAS mutations.
RO7673396 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY on the OTC market. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational oncology drug.
RO7673396 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The Phase 1 study is currently recruiting participants to evaluate the drug's safety, tolerability, and preliminary clinical activity.
RO7673396 is being studied in a Phase 1 clinical trial with the identifier NCT06884618. This trial is evaluating the safety, tolerability, pharmacokinetics, and preliminary clinical activity of RO7673396 in participants with advanced solid tumors harboring RAS mutations. The study is recruiting and aims to enroll 405 participants across multiple countries.
RO7673396 is a distinct investigational small molecule being developed by Roche. It is designed to target tumors with RAS mutations, a class of genetic alterations found in many cancers. While other drugs may also target RAS mutations, RO7673396 is a unique compound with its own chemical structure and clinical development program.